Scade Medical, (http://scademedical.com) was founded in 2013 by Dr. Ofir Aharon and Mr. Gabi Mizrahi along with first two investors Mr. Shlomi Swissa and Mr.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved ProAir® Digihaler™ (albuterol sulfate 117

Sight Diagnostics (SightDX), a portfolio company of Anatomy, Clal Biotechnology’s investment fund for medical devices, had raised $28 million. When the round is completed, Anatomy’s

Ran Poliakine, founder and former CEO of Powermat, has established a new Innovation Center designed to foster and develop new and emerging wearable technologies. The Innovation

RenalSense®  is conducting a pilot study with its Clarity RMS® critical care monitoring system at the University of Pittsburgh Medical Center (UPMC), under the direction of Professor

BrainsWay‘s deep transcranial magnetic stimulation (Deep TMS) system was one of only eight medical devices selected by the U.S. Food and Drug Administration (FDA) from

Pepticom was honored with an image from their article on this December’s Journal of Immunology. The image is taken from Pepticom’s latest article “Computationally Designed Bispecific

While current immunotherapies offer promise to previously untreatable cancers, they only work in a small percentage of patients with certain types of cancer. Scientists have

Bioblast Pharma Ltd. (Nasdaq:ORPN) announced the execution of a definitive agreement to acquire Enlivex Therapeutics Ltd., a VC-funded privately-held immunotherapy company. Upon closing of the